/

Sociétés

Tu

Non vérifié

Tubulis

Ce que nous écrivons

BiotechnologieIndustrie pharmaceutiqueOncologieSantéScience

14 communiqués de presse

Voir tous les communiqués de presse

27/01/2026

Oncologie

Santé

Médecine - Divers

Science

Industrie pharmaceutique

Biotechnologie

Marché du travail

Tubulis Adds Steve Kelsey as Independent Director to its Advisory Board

Source

Émetteur

1.00

0

21/01/2026

Science

Biotechnologie

Industrie pharmaceutique

Oncologie

Santé

Industrie

Tubulis Unveils Alco5 Conjugation Platform’s Ability to Expand ADC Payload Scope in Nature Communications

Source

Émetteur

1.00

0

08/01/2026

Science

Biotechnologie

Industrie pharmaceutique

Oncologie

Santé Publique

Santé

Médecine - Divers

Marché du travail

Tubulis Appoints Charles Fuchs, MD as Chief Medical Officer to Lead Clinical Strategy and Pipeline Development

Source

Émetteur

1.00

0

16/12/2025

Événements

Santé Publique

Santé

Industrie pharmaceutique

Médecine - Divers

Oncologie

Tubulis to Present at the 44th Annual J.P. Morgan Healthcare Conference

Source

Émetteur

1.00

0

30/10/2025

Biotechnologie

Santé Publique

Santé

Industrie pharmaceutique

Oncologie

Science

Vitrines/Shopping

Médecine - Divers

Tubulis Announces Second Closing of Series C Bringing Total Raised to €344M (US $401M)

Source

Émetteur

1.00

0

19/10/2025

Science

Médecine - Divers

Biotechnologie

Industrie pharmaceutique

Vitrines/Shopping

Santé

Oncologie

Événements

Industrie

Tubulis Presents First Clinical Data from Phase I/IIa Trial for TUB-040 in Platinum-Resistant Ovarian Cancer (PROC) at ESMO 2025

Source

Émetteur

1.00

0

15/10/2025

Oncologie

Santé

Médecine - Divers

Science

Industrie pharmaceutique

Biotechnologie

Tubulis Raises €308 Million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline

Source

Émetteur

1.00

0

22/09/2025

Événements

Industrie

Oncologie

Santé

Médecine - Divers

Science

Industrie pharmaceutique

Biotechnologie

Tubulis to Present First Phase I/IIa Trial Data for ADC Candidate TUB-040 in Platinum-Resistant Ovarian Cancer in Late-Breaking Oral Presentation at ESMO 2025

Source

Émetteur

1.00

0

09/09/2025

Science

Lois/Droit

Biotechnologie

Industrie pharmaceutique

Oncologie

Santé

Associations/Professionnels

Marché du travail

Tubulis Strengthens Leadership Team with Appointment of Halley Gilbert as Chief Legal and Operating Officer

Source

Émetteur

1.00

0

06/02/2025

Oncologie

Santé

Science

Industrie pharmaceutique

Biotechnologie

Marché du travail

Tubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc.

Source

Émetteur

1.00

0

Followers

0

Compatibilité

0